Swedbank AB Decreases Stock Position in Pfizer Inc. $PFE

Key Points

• Swedbank AB has decreased its stock holdings in Pfizer Inc. by 13.8% in the first quarter, now owning approximately 4.42 million shares valued at $112 million.
• Pfizer's quarterly earnings exceeded analyst expectations, reporting $0.78 EPS against a consensus estimate of $0.58, with revenues of $14.65 billion.
• The company's stock is currently rated with a consensus of "Hold" and a price target of $28.12, while shares are trading down 3.8% to around $23.91.

Swedbank AB cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 13.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,422,401 shares of the biopharmaceutical company's stock after selling 708,773 shares during the quarter. Swedbank AB owned about 0.08% of Pfizer worth $112,064,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. William B. Walkup & Associates Inc. raised its stake in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co raised its stake in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its stake in shares of Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the last quarter. MSH Capital Advisors LLC raised its stake in shares of Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after purchasing an additional 485 shares during the last quarter. Finally, Signature Estate & Investment Advisors LLC raised its stake in shares of Pfizer by 2.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock worth $488,000 after purchasing an additional 486 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Down 3.8%

Shares of NYSE:PFE opened at $23.91 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a market capitalization of $135.94 billion, a PE ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The business has a 50 day moving average of $24.79 and a two-hundred day moving average of $24.30. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.